Skip to main content

TNF inhibitor

Reader beware! Interpretation of effectiveness & safety of JAKi vs bDMARDs in real world data

Multiple studies compared effectiveness, retention and/or safety of biological DMARDs (bDMARDs) and JAK inhibitors (JAKi) at EULAR 2021. But be careful of what you read because depending on age, gender, comorbidities, line of therapy and access to treatment, you may find highly variable

Read Article

EULAR 2021 – Day 4 Report

Jun 17, 2021

It's been nearly two weeks since EULAR 21 ended. There were several presentations on the last day; notably, the late breaking abstracts and others. Here are a few of my favorites from Day 4, the final day of the meeting.

Read Article

RheumNow Podcast - Best of EULAR 2021

Jun 11, 2021

Dr. Jack Cush reviews and highlights his favorite abstracts and presentations from last week's virtual EULAR 2021 meeting.

Read Article

Novel TYK2 Inhibitor Efficacious for Treatment of Psoriatic Arthritis

Dr. Philip Mease et al presented results of a phase II trial (OP0227) at EULAR 2021 that shows the efficacy and safety of an oral tyrosine kinase inhibitor (TYKi), deucravacitinib, for treatment of active psoriatic arthritis (PsA).

Read Article

How do we personalize psoriatic arthritis treatment?

Jun 07, 2021

It seems like every conference we are presented with data on the newest biologic for treatment of psoriatic arthritis, but the question is, do we need it?



Oral presentation (6937) discussed that issue and addressed our need for a more personalized approach to the treatment of PsA. 

Read Article
@almirall_m I don't monitor routinely. High rate of seroconversion post-TNFi but only small cases of TNFi-induced SLE (mild mostly). To screen with ANA if develop SLE features

Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )

Jun 05, 2021
Due to significant interest in our Tweet about #POS0204 #EULAR2021, let's vote. Would you monitor #ANA in patients receiving therapy with #TNF inhibitors?🧐@RheumNow

Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )

Jun 05, 2021
Yesterday at #EULAR2021: Spacing trial: success in taper anti-TNF for stable SpA. POS0229 C-OPTIMSE study: Certolizumab w/d for SpA remission (continue full dose vs. 1/2 dose vs. placebo). Placebo group had ⬆️ activity scores, 77% flared. Ok to taper, but won't stop Rx @Rheumnow

Eric Dein @ejdein1( View Tweet )

Jun 05, 2021
#EULAR2021 and EULAR IQ Dr Jack Cush reviews highlight presentations from the first 3 days of EULAR 2021. https://t.co/BkHjhOUqNU https://t.co/4JS1yGiJHg
Dr. John Cush @RheumNow( View Tweet )
Jun 05, 2021
2021 GRAPPA STRONG recs (cont'd): *⃣Crohn's Dz & UC: TNFi (not ETN), IL12/23i 🚫strong rec against IL17i 2021 GRAPPA CONDITIONAL recs for: *⃣ Uveitis: TNFi (not ETN), CyA *⃣ Crohn's Dz & UC: IL23i, JAKi, MTX OP0229 #EULAR2021 @RheumNow https://t.co/AWyKqSapWG
Meral K. El Ramahi, MD @MeralElRamahiMD( View Tweet )
Jun 04, 2021
Sex differences in response to bDMARDs in RA, PsA & SpA? YES. Data from BIOREG- 477 RA, 150 PsA, 312 SpA treated with rap TNFi. Men respond better to TNFi in all groups POS0208 #EULAR2021 @RheumNow @eular_org https://t.co/7FoI3p0qwe
Janet Pope @Janetbirdope( View Tweet )
Jun 04, 2021

EULAR 2021 - Day 2 Podcasts

Jun 04, 2021

Check out this compilation of our EULAR 2021 Day 2 broadcasts below.



You can also follow the EULAR 2021 RheumNow podcasts on iTunes and Soundcloud.com



Listen by Clicking below:



1. EULAR2021 - Day2a



Read Article

The COSMOS study results showed that GUS 100 mg Q8W showed ⬆️ ACR20 vs PBO at W24 in TNFi IR PsA pts who had tried 1-2 prior TNFi. What MOA do you choose after 1st TNFi IR in your PsA pts? Abstract #OP0230 #EULAR2021 @RheumNow https://t.co/Jb7GqkHtYz

Dr. Rachel Tate @uptoTate( View Tweet )

Jun 04, 2021

RheumNow Podcast - EULAR 2021 & EULAR-IQ (6.4.21)

Jun 04, 2021

Dr Jack Cush reviews highlight presentations from the first 3 days of EULAR 2021.


Read Article

EULAR 2021 – Day 2 Report

Jun 04, 2021

During Day 2 there were great sessions devoted to RA, spondylarthritis, fatigue and more.  Here are some of my highlights from Day 2.

Read Article
Prospective analysis #OP0220 showed that PsA pt age, dz duration and activity level at tx initiation have ⬇️ with TNFi over the past 20 years. TNFi retention rates have ⬇️ while remission rates have ⬆️ (notably those in 1st yr tx) #EULAR2021 @RheumNow https://t.co/gnKRfvbHPQ https://t.co/PRunGIxMwx
Dr. Rachel Tate @uptoTate( View Tweet )
Jun 04, 2021
Very informative #EULAR2021 WIN session on MIS-C @EULAR_org 👉 Steroids early 👉 IVIg in all 👉 anticoagulant use remains variable #Coronary aneurysms ✅ occur during acute phase in MIS-C and improve with treatment ✅ occur in the late/convalescent phase of #Kawasaki disease https://t.co/Ff3rX6u5VK
Ashima Makol MD @AshimaMakol( View Tweet )
Jun 03, 2021
Do you increase spacing of TNF-i administration in your patients with axSpA with sustained low disease activity for one year? OP0138 results showed similar relapse rates in those with increased spacing intervals and those on standard dosing regimen. #EULAR2021 @RheumNowNews

Meral K. El Ramahi, MD @MeralElRamahiMD( View Tweet )

Jun 03, 2021
#EULAR2021 OP0138 - Radiographic AxSpA in LDA, SPACING anti-TNF vs continue care. 83% were able to ⬆️ dosing interval at month 12, drug efficacy recovered in pts with relapsed disease. Worth trying in stable patient who wants to wean down meds. @RheumNow

Eric Dein @ejdein1( View Tweet )

Jun 03, 2021
➡️ASTERA = PIII trial that showed superior efficacy of Netakimab (IL-17Ai) vs PBO in pts w/ active r-axSpA. Excluded pts prev tx w/ 2 or more TNFi ➡️OP0142 = sub-analysis showing Netak ⬇️ dz activity in AS pts irrespective of sacroillitis on MRI at b/l #EULAR2021 @Rheumnow https://t.co/faT3M0xQiR
Meral K. El Ramahi, MD @MeralElRamahiMD( View Tweet )
Jun 03, 2021
⭐️All cancer excluding NMSC - 0.9HR TNFi vs cDMARD ⭐️Squamous cell CA - 1.2HR of TNFi vs cDMARD ⭐️No overall increase in all CA: RTX, TOCI ⭐️Abatacept 1.21HR for all cancer, mainly NMSC ⭐️needs more data on JAKs, IL-17, IL-23 Abs#6916 #EULAR2021 @RheumNow

Robert B Chao, MD @doctorRBC( View Tweet )

Jun 03, 2021
From bedside to bench–unexpected results of clinical studies that changed our understanding of the disease #EULAR2021. “SpA” talk by Prof. Désirée van der Heijde. Inhibition of TNF, IL-17, IL-23, IL-6, IL-1, co-stimulation and B cell depletion in immunology perspective 👏 /TK https://t.co/JFr3VC8sXY
ARD & RMD Open @ARD_BMJ( View Tweet )
Jun 03, 2021
TNFi use associated with ⬇️ radiographic sacroilitis progression in patients with AxSpA ⭐️effect becomes evident between 2 and 4 years after treatment Abs#OP0137 #EULAR2021 @RheumNow

Robert B Chao, MD @doctorRBC( View Tweet )

Jun 03, 2021
SPACING trial OP0138 at #EULAR2021 ⭐️RCT by the French showing non-inferiority of spacing TNFi in r-axSpA pts w/ LDA (BASDAI<4 x 6mo) ⭐️ 88% in spacing group remained w/ LDA vs 91.5% in standard tx ⭐️ADA, CTZ, GOL, IFX spaced by 1w intervals. ETN by 3-4d & 1w. @RheumNow

Meral K. El Ramahi, MD @MeralElRamahiMD( View Tweet )

Jun 03, 2021
Dr Lukas presents data showing possibility of tapering a range of TNF in AxSpA patients in remission 162/184 (88.0%) LDA in progressive spacing group vs 173/189 (91.5%) in continued at 1 year.@RheumNow #EULAR2021 Abstr#0138

Richard Conway @RichardPAConway( View Tweet )

Jun 03, 2021
×